[2]
Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet 1998; 1801-7.
[5]
Michael P. Process for preparing a crystalline form of atorvastatin hemi-calcium WO 2007/103223 A1, 2007.
[6]
Roth BD. [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy- 5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof US 5,273,995, 1993.
[7]
Srinivasulu G, Srinivas K, Satyanarayana K, Satyanarayanajaya K. WO 2006/039443 A2 2006.
[8]
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
[9]
Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
[10]
Steiner S, Niessner A, Ziegler S, et al. Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease. Atherosclerosis 2005; 181: 305-10.
[11]
Qandil AM, Rezigue MM, Tashtoush MM. Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. Eur J Pharm Sci 2011; 43: 99-108.
[12]
Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405: 421-42.
[13]
Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: From orphan receptors to drug discovery. J Med Chem 2000; 43: 527-50.
[14]
Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001; 3: 83-92.
[15]
Aberg F, Appelkvist EL, Broijersen A, et al. Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia. Eur J Clin Invest 1998; 28: 235-42.
[16]
Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998; 34: 155-62.
[17]
Lovreka M, Zorc B, Boneschans B, Butula I. Macromolecular prodrugs. VIII. Synthesis of polymer – gemfibrozil conjugates. Int J Pharm 2000; 200: 59-66.
[18]
Lupp A, Karge E, Hopf H, Machts H, Oelschläger H, Fleck C. Fibrates and their newly synthesized glycinate or glycinate-methylester derivatives: Comparison of the interactions with liver cytochrome P450 dependent monooxygenase- and oxidase-functions in vitro. Exp Toxicol Pathol 2003; 54: 433-40.
[19]
Jensen GR. Handbook of milk composition, San Diego 1975. CA: Academic Press Inc 1995.
[20]
Sunder R, Akesson B. Regulation of phospholipid biosynthesis in isolated rat hepatocytes. J Biol Chem 2006; 250: 3350-67.
[21]
Delong CJ, Shen YJ, Thomas MJ, Cui Z. Molecular distinction of phosphatidylcholine synthesis between the CDP-choline pathway and phosphatidylethanolamine methylation pathway. J Biol Chem 1999; 274: 29683-8.
[22]
Reo NV, Adinehzadeh M, Foy BD. Kinetic analysis of liver phosphatidylcholine and phosphatidylethanolamine biosynthesis using d13TC NMR spectroscopy. Biochim Biophys Acta 2002; 1580: 171-88.
[23]
Watkins MS, Zhu X, Zeisel HS. Phosphatidylethanolamine-N methyltransferase activity and dietary choline regulate liver-plasma lipid flux and essential fatty acid metabolism in mice. J Nutr 2003; 133: 3386-91.
[24]
Shimada Y, Morita T, Sugiyama K. Dietary eritadenine and ethanolamine depress fatty acid desaturase activities by increasing liver microsomal phosphatidylethanolamine in rats. J Nutr 2003; 133: 758-65.
[25]
Imaizumi K, Sakano M, Wawatari K, Murata M, Sugano M. Effect of phosphatidylethanolamine and its constituent base on the metabolism of linoleic acid in rat liver. Biochim Biophys Acta 1989; 1005: 253-9.
[26]
Kume H, Tsukahara K, Okazaki K, Sasaki H. Milk-derived phospholipids prevent the development of hypercholesterolemia and hepatic steatosis in rats fed high cholesterol/triglyceride diets. J Metab Clin Nutr 2004; 3: 187-95.
[27]
Kume H, Tsukahara K, Okazaki K, Sasaki H. Ethanolamine improves hypercholesterolemia in rats fed high-fat/high-cholesterol diets. Nutr Res 2006; 26: 573-8.
[28]
Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: Design and clinical applications. Nat Rev Drug Discov 2008; 7: 255-70.
[29]
Cynkowska G, Cynkowski T, Al-Ghananeem AM, Guo H, Ashton P, Crooks PA. Novel antiglaucoma prodrugs and codrugs of ethacrynic acid. Bioorg Med Chem Lett 2005; 15: 3524-7.
[30]
Dhaneshwar SS, Gairola N, Kandpal M, et al. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon specific drug delivery in inflammatory bowel disease. Eur J Med Chem 2009; 44: 3922-9.
[31]
Hamad MO, Kiptoo PK, Stinchcomb AL, Crooks PA. Synthesis and hydrolytic behavior of two novel tripartite codrugs of naltrexone and 6β-naltrexol with hydroxybupropion as potential alcohol abuse and smoking cessation agent. Bioorg Med Chem 2006; 14: 7051-61.
[32]
Abdel-Azeem AZ, Abdel-Hafez AA, El-Karamany GS, Farag HH. Chlorzoxazone esters of some non-steroidal anti-inflammatory (NSAI) carboxylic acids as mutual prodrugs: Design, synthesis, pharmacological investigations and docking studies. Bioorg Med Chem 2009; 17: 3665-70.
[33]
Sudha SS, Karthic R, Naveen RJ. Anti hyperlipidemic activity of Spirulina platensis in Triton X-100 induced hyperlipidemic rats. Hygeia J D Med 2011; 3: 32-7.
[34]
Glide; Maestro, version 90, Schrödinger, LLC, New
York, NY,. 2009.
[35]
LigPrep, version 23, Schrödinger, LLC, New York,
NY,. 2009.
[36]
Bernardes A, Souza PCT, Muniz JRC, et al. Molecular mechanism of peroxisome proliferator-activated receptor α activation by WY14643: A new mode of ligand recognition and receptor stabilization. J Mol Biol 2013; 423: 2878-93.
[37]
Teli MK, Rajanikant GK. Identification of novel potential HIF-prolyl hydroxylase inhibitors by in silico screening. Mol Divers 2012; 16: 193-202.
[38]
QikProp, version 32, Schrödinger, LLC, New York,
NY. 2009.
47
3
1
3